K. Karwowska

Ebola virus disease

K. Karwowska, H. D. Clerck, J. Griensven, 2019, The Lancet.

Real‐world effectiveness and safety of ombitasvir/paritaprevir/ritonavir ± dasabuvir ± ribavirin in hepatitis C: AMBER study

K. Simon, A. Horban, E. Janczewska, 2016, Alimentary pharmacology & therapeutics.

Renal impairment in patients with chronic hepatitis C treated with first generation protease inhibitors

K. Karwowska, D. Dybowska, M. Wietlicka-Piszcz, 2015, Expert opinion on drug safety.

Five-Year Follow-Up of Cured HCV Patients under Real-World Interferon-Free Therapy

E. Janczewska, R. Flisiak, K. Karwowska, 2021, Cancers.

The Two-Sided Experimental Model of ImmunoCAP Inhibition Test as a Useful Tool for the Examination of Allergens Cross-Reactivity on the Example of α-Gal and Mammalian Meat Sensitization—A Preliminary Study

M. Pawłowska, K. Karwowska, Z. Bartuzi, 2023, Current issues in molecular biology.

Durability of virologic response, risk of de novo hepatocellular carcinoma, liver function and stiffness 2 years after treatment with ombitasvir/paritaprevir/ritonavir±dasabuvir±ribavirin in the AMBER, real‐world experience study

K. Simon, E. Janczewska, R. Flisiak, 2018, Journal of viral hepatitis.

Agranulocytosis during treatment of chronic hepatitis C complicated by hyperthyreosis. Case reports.

K. Karwowska, W. Halota, D. Dybowska, 2012, Endokrynologia Polska.

[Leptospirosis--disease with many faces].

K. Karwowska, W. Halota, D. Kozielewicz, 2013, Polski merkuriusz lekarski : organ Polskiego Towarzystwa Lekarskiego.

Effect of comedication on ombitasvir/paritaprevir/ritonavir ± dasabuvir ± ribavirin therapy in chronic hepatitis C – a real-world study

K. Simon, A. Horban, E. Janczewska, 2019, Clinical and experimental hepatology.